T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma

Outcomes for patients with glioblastoma (GBM) remain poor despite aggressive multimodal therapy. Immunotherapy with genetically modified T cells expressing chimeric antigen receptors (CARs) targeting interleukin (IL)-13Rα2, epidermal growth factor receptor variant III (EGFRvIII), or human epidermal...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chow, Kevin KH, Naik, Swati, Kakarla, Sunitha, Brawley, Vita S, Shaffer, Donald R, Yi, Zhongzhen, Rainusso, Nino, Wu, Meng-Fen, Liu, Hao, Kew, Yvonne, Grossman, Robert G, Powell, Suzanne, Lee, Dean, Ahmed, Nabil, Gottschalk, Stephen
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3589173/
https://ncbi.nlm.nih.gov/pubmed/23070117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2012.210
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares